https://www.prnewswire.com/news-releases/hansa-biopharma-expects-strong-first-quarter-2024-sales-performance-302105212.html
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
/PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited),...
hansa biopharmafirst quarter2024 salesstrongperformance
https://www.nasdaq.com/market-activity/stocks/hnsbf
Hansa Biopharma AB (HNSBF) Stock Price, Quote, News & History | Nasdaq
Discover real-time Hansa Biopharma AB (HNSBF) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay...
hansa biopharmastock pricenews historyabquote
https://www.hansabiopharma.com/
Hansa Biopharma - Home
We develop lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.
hansa biopharma
https://www.home.saxo/pl-pl/markets/stocks/hnsa-xome
Hansa Biopharma AB akcja | Saxo Bank
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies...
hansa biopharmaabakcjasaxobank
https://www.fiercebiotech.com/keyword/hansa-biopharma
Hansa Biopharma | Fierce Biotech
hansa biopharmafiercebiotech
https://www.prnewswire.com/news-releases/hansa-biopharma-interim-report-january--march-2022-301529853.html
Hansa Biopharma interim report January - March 2022
/PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and...
hansa biopharmainterim reportjanuarymarch2022
https://www.prnewswire.com/news-releases/hansa-biopharma-completes-enrolment-in-global-pivotal-phase-3-trial-of-imlifidase-in-anti-glomerular-basement-membrane-disease-302323969.html
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in...
/PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a...
phase 3 trialhansa biopharma
https://www.prnewswire.com/news-releases/hansa-biopharma-provides-business-update-including-certain-key-financials-301456756.html
Hansa Biopharma provides business update including certain key financials
/PRNewswire/ -- Commercial launch and market access efforts in Europe progressing as planned; New multiregional commercialization partnership with Medison in...
hansa biopharmabusiness updateprovidesincludingcertain
https://www.prnewswire.com/news/hansa-biopharma-ab/?page=8&pagesize=25
Hansa Biopharma AB News and Press Releases | PR Newswire
news and press releaseshansa biopharmaabnewswire
https://www.prnewswire.com/news-releases/hansa-biopharma-interim-report-january-march-2024-302120655.html
Hansa Biopharma interim report January-March 2024
/PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and...
hansa biopharmainterim reportjanuarymarch2024
https://www.home.saxo/nl-be/markets/stocks/hnsa-xome
Hansa Biopharma AB aandeel | Saxo Bank
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies...
hansa biopharmaabaandeelsaxobank
https://www.prnewswire.com/news/hansa-biopharma-ab/?page=9&pagesize=25
Hansa Biopharma AB News and Press Releases | PR Newswire
news and press releaseshansa biopharmaabnewswire
https://www.biospace.com/hansa-biopharma-to-host-conference-call-to-provide-half-year-results-for-january-june-2023-and-a-business-update
Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a...
Jul 6, 2023 - Hansa Biopharma AB will publish its interim report for January-June 2023 at 8:00 CET on July 20, 2023.
https://www.biospace.com/hansa-biopharma-enrolls-first-patient-in-u-s-randomized-controlled-pivotal-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients
Hansa Biopharma enrolls first patient in U.S. randomized, controlled pivotal trial of imlifidase in...
Dec 29, 2021 - Hansa Biopharma AB "Hansa", the pioneer in IgG-cleaving enzyme technology for rare immunological conditions, announces that the first patient in its U.S....
https://www.prnewswire.co.uk/news-releases/hansa-biopharma-reports-third-quarter-and-interim-year-to-date-2025-financial-results-302599425.html
Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results
/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-September 2025....
year to date
https://www.prnewswire.com/news-releases/hansa-biopharma-announces-positive-topline-data-from-the-imlifidase-phase-2-study-in-antibody-mediated-rejection-amr-episodes-post-kidney-transplantation-301688075.html
Hansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody...
Data readout demonstrates a significantly superior capacity of imlifidase to rapidly reduce levels of donor-specific antibodies (DSAs) compared to plasma...
https://www.prnewswire.com/news-releases/hansa-biopharma-announces-70-million-non-dilutive-product-finance-transaction-with-novaquest-to-support-continued-development-of-the-companys-antibody-cleaving-enzyme-technology-platform-301588530.html
Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to...
Proceeds will be mainly utilized to: - Further strengthen the Company's position in kidney transplantation through the continued support of ongoing European...
https://www.prnewswire.com/news-releases/hansa-biopharma-to-host-conference-call-to-provide-interim-results-for-january-september-2022-and-business-update-301637644.html
Hansa Biopharma to host conference call to provide interim results for January-September 2022 and...
/PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA) will publish its interim report for January-September 2022 at 8:00 CET on October 20, 2022. All...
https://www.prnewswire.com/news-releases/hansa-biopharma-announces-first-patient-treated-in-the-post-authorization-efficacy-study-paes-of-idefirix-imlifidase-in-highly-sensitized-kidney-transplant-patients-301583553.html
Hansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of...
/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, announces today that...